ViiV Preps Once-Daily Integrase Inhibitor '572 For Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II results presented at International AIDS Society meeting fuel speculation about co-formulations with other HIV drugs, including ViiV's Epzicom and Gilead's Truvada.